Inj. Humalog Mix (50% + 50%) / sc injection | VetSafeCare.Com

Inj.

Humalog Mix

Insulin Lispro Protamine + Insulin Lispro — Eli Lilly and Company
(50% + 50%) / sc injection · 3 ml

Alternatives

1

Routes

SC

Presentations

4

Brand overview Generic profile Browse alternatives

Presentation

Inj. Humalog Mix

SC Injection · Subcutaneous · (50% + 50%) / sc injection · 3 ml

৳1347.56

Dose rules

No structured dose rules are linked to this brand yet.

Dose reference

Human

Combination rapid-onset (faster than regular insulin) and intermediate-acting insulins in fixed dose. Dose regimen varies among patients depending on metabolic needs; typical daily insulin requirements range between 0.5-1 unit/kg

Clinical notes

Applications:

N/A

Indication Notes:
A mixture of 75% insulin lispro protamine suspension and 25% insulin lispro injection, (rDNA origin), is indicated in the treatment of patients with diabetes mellitus for the control of hyperglycemia.A mixture of 50% insulin lispro protamine suspension and 50% insulin lispro injection, (rDNA ... Read moreA mixture of 75% insulin lispro protamine suspension and 25% insulin lispro injection, (rDNA origin), is indicated in the treatment of patients with diabetes mellitus for the control of hyperglycemia.A mixture of 50% insulin lispro protamine suspension and 50% insulin lispro injection, (rDNA origin), is also indicated in the treatment of patients with diabetes mellitus for the control of hyperglycemia.
Avoid In:

N/A

Contraindication Notes:
Insulin Lispro Protamine & Insulin Lispro is contraindicated during episodes of hypoglycemia and in patients sensitive to insulin lispro or any of the excipients contained in the formulation
Insulin lispro is a short-acting biosynthetic human insulin analogue. Insulin lispro protamine is an intermediate-acting glucose-lowering agent; it is a suspension of crystals produced from combining insulin lispro and protamine sulfate under appropriate conditions for crystal formation. They are used together for the regulation of glucose metabolism.
Effects may be increased by: oral antidiabetic agents, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics. Effects may be decreased by: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, oral contraceptives, lithium. Signs of hypoglycaemia may be masked by beta-blockers, clonidine.
Hypoglycaemia; hypokalemia, oedema; pruritus; pulpitation, nausea, rash; hypersensitivity reactions; lipoatropy or lipohypertrophy with SC Inj.
Pregnancy Category B. Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.Lactation: Unknown whether distributed in breast milk; compatible with breast feeding, but lactating women may require dosage adjustment; caution advised
Renal or hepatic impairment; pregnancy, lactation; transferring from other insulin. Monitor serum glucose, potassium, electrolytes, HbA1c and lipid profile. Concomitant illness esp infections.